Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

French ccAFU guidelines – Update 2018–2020: Bladder cancer

Rouprêt M, Neuzillet Y, Pignot G, Compérat E, Audenet F, Houédé N, Larré S, Masson-Lecomte A, Colin P, Brunelle S, Xylinas E, Roumiguié M, Méjean A.

Prog Urol. 2019 Sep 20;28(S1):R48-R80. doi: 10.1016/j.purol.2019.01.006. French.

PMID:
32093463
2.

Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group.

Sroussi M, Elaidi R, Fléchon A, Lorcet M, Borchiellini D, Tardy MP, Gravis G, Guérin M, Laguerre B, Estrade F, Delva R, Barthélémy P, Loriot Y, Lavaud P, Lebret T, Neuzillet Y, Penel N, Houede N, Pouessel D, Rousseau B, Mussat E, Gross-Goupil M, Culine S, Gauthier H, Gobert A, Roupret M, Huillard O, Tartas S, Radulescu C, Allory Y, Oudard S.

Clin Genitourin Cancer. 2019 Dec 5. pii: S1558-7673(19)30365-9. doi: 10.1016/j.clgc.2019.11.014. [Epub ahead of print]

PMID:
31882335
3.

[French ccAFU guidelines - Update 2018-2020: Upper tract urothelial carcinoma].

Rouprêt M, Xylinas E, Colin P, Houédé N, Compérat E, Audenet F, Larré S, Masson-Lecomte A, Pignot G, Brunelle S, Roumiguié M, Neuzillet Y, Méjean A.

Prog Urol. 2018 Nov;28 Suppl 1:R34-R47. doi: 10.1016/j.purol.2019.01.005. Epub 2019 Aug 23. French.

PMID:
31610873
4.

[Immunotherapy in urology: Concept and results].

Pignot G, Houede N.

Prog Urol. 2019 Nov;29(15):922-928. doi: 10.1016/j.purol.2019.08.267. Epub 2019 Aug 30. French.

PMID:
31477432
5.

Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?

Bersanelli M, Iacovelli R, Buti S, Houede N, Laguerre B, Procopio G, Lheureux S, Fischer R, Negrier S, Ravaud A, Oudard S, Escudier B, Albiges L, Porta C.

Eur Urol Oncol. 2019 Jul 19. pii: S2588-9311(19)30099-9. doi: 10.1016/j.euo.2019.06.018. [Epub ahead of print]

PMID:
31331862
6.

[Management of patients with systemic treatments].

Houédé N.

Prog Urol. 2019 Jun;29 Suppl 1:S42-S50. doi: 10.1016/S1166-7087(19)30169-1. French.

PMID:
31307630
7.

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

Flippot R, Dalban C, Laguerre B, Borchiellini D, Gravis G, Négrier S, Chevreau C, Joly F, Geoffrois L, Ladoire S, Mahammedi H, Rolland F, Gross-Goupil M, Deluche E, Priou F, Laramas M, Barthélémy P, Narciso B, Houedé N, Culine S, Oudard S, Chenot M, Tantot F, Chabaud S, Escudier B, Albiges L.

J Clin Oncol. 2019 Aug 10;37(23):2008-2016. doi: 10.1200/JCO.18.02218. Epub 2019 Jun 13.

PMID:
31194611
8.

[Care of advanced or metastatic bladder cancer in second line: A specific place for vinflunine].

Houédé N, Milano G.

Bull Cancer. 2019 May;106(5):431-435. doi: 10.1016/j.bulcan.2019.02.007. Epub 2019 Apr 10. French.

PMID:
30981463
9.

Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.

Oudard S, Latorzeff I, Caty A, Miglianico L, Sevin E, Hardy-Bessard AC, Delva R, Rolland F, Mouret L, Priou F, Beuzeboc P, Gravis G, Linassier C, Gomez P, Voog E, Muracciole X, Abraham C, Banu E, Ferrero JM, Ravaud A, Krakowski I, Lagrange JL, Deplanque G, Zylberait D, Bozec L, Houede N, Culine S, Elaidi R.

JAMA Oncol. 2019 May 1;5(5):623-632. doi: 10.1001/jamaoncol.2018.6607.

10.

[Short version of recommendations for enhanced recovery program (ERP) for cystectomy: Technical measures].

Poinas G, Blache JL, Kassab-Chahmi D, Evrard PL, Artus PM, Alfonsi P, Rébillard X, Beaussier M, Cerantola Y, Coloby P, Drapier É, Houédé N, Masson-Lecomt A, Rouprêt M, Le Normand L, Gamé X, Bosset PO, Delaunay L, Fendler JP, Ecoffey C, Cuvelier G.

Prog Urol. 2019 Feb;29(2):63-75. doi: 10.1016/j.purol.2018.12.002. Epub 2019 Jan 8. Review. French.

PMID:
30635149
11.

Clinical Relevance of Routine Monitoring of Patient-reported Outcomes Versus Clinician-reported Outcomes in Oncology.

Fiteni F, Cuenant A, Favier M, Cousin C, Houede N.

In Vivo. 2019 Jan-Feb;33(1):17-21. doi: 10.21873/invivo.11433. Review.

12.

RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU — Actualisation 2018—2020 : tumeurs de la vessie French ccAFU guidelines — Update 2018—2020: Bladder cancer

Rouprêt M, Neuzillet Y, Pignot G, Compérat E, Audenet F, Houédé N, Larré S, Masson-Lecomte A, Colin P, Brunelle S, Xylinas E, Roumiguié M, Méjean A.

Prog Urol. 2018 Nov;28(12S):S46-S78. doi: 10.1016/j.purol.2018.07.283. Epub 2018 Oct 23. Review. French.

PMID:
30366708
13.

RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU — Actualisation 2018—2020 : tumeurs de la voie excrétrice supérieure French ccAFU guidelines — Update 2018—2020: Upper tract urothelial carcinoma

Rouprêt M, Xylinas E, Colin P, Houédé N, Compérat E, Audenet F, Larré S, Masson-Lecomte A, Pignot G, Brunelle S, Roumiguié M, Neuzillet Y, Méjean A.

Prog Urol. 2018 Nov;28(12S):S32-S45. doi: 10.1016/j.purol.2018.07.284. Epub 2018 Oct 11. Review. French. Erratum in: Prog Urol. 2018 Nov;28 Suppl 1:R34-R47.

PMID:
30318333
14.

Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study.

Guillot A, Joly C, Barthélémy P, Meriaux E, Negrier S, Pouessel D, Chevreau C, Mahammedi H, Houede N, Roubaud G, Gravis G, Tartas S, Albiges L, Vassal C, Oriol M, Tinquaut F, Espenel S, Bouleftour W, Culine S, Fizazi K.

Clin Genitourin Cancer. 2019 Feb;17(1):e38-e43. doi: 10.1016/j.clgc.2018.08.006. Epub 2018 Sep 6.

PMID:
30279115
15.

[ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology].

Pignot G, Houédé N, Roumiguié M, Audenet F, Brunelle S, Colin P, Compérat E, Larré S, Masson-Lecomte A, Neuzillet Y, Xylinas E, Méjean A, Rouprêt M; les membres du CCAFU Vessie.

Prog Urol. 2018 Oct;28(12):567-574. doi: 10.1016/j.purol.2018.07.003. Epub 2018 Sep 8. Review. French.

PMID:
30205925
16.

[Impacts of routine patient-reported-outcomes monitoring in oncology].

Fiteni F, Favier M, Bascoul-Mollevi C, Gourgou S, Cousin C, Houédé N.

Bull Cancer. 2018 Sep;105(9):847-848. doi: 10.1016/j.bulcan.2018.06.010. Epub 2018 Jul 20. French. No abstract available.

PMID:
30032955
17.

Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.

Rouanne M, Roumiguié M, Houédé N, Masson-Lecomte A, Colin P, Pignot G, Larré S, Xylinas E, Rouprêt M, Neuzillet Y.

World J Urol. 2018 Nov;36(11):1727-1740. doi: 10.1007/s00345-018-2332-5. Epub 2018 Jun 1. Review.

PMID:
29855698
18.

Enterocolitis in Patients with Cancer Treated with Docetaxel.

Fiteni F, Paillard MJ, Orillard E, Lefebvre L, Nadjafizadeh S, Selmani Z, Benhamida S, Roland A, Baumann A, Vienot A, Houédé N, Pivot X.

Anticancer Res. 2018 Apr;38(4):2443-2446.

PMID:
29599375
19.

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.

Pulido M, Roubaud G, Cazeau AL, Mahammedi H, Vedrine L, Joly F, Mourey L, Pfister C, Goberna A, Lortal B, Bellera C, Pourquier P, Houédé N.

BMC Cancer. 2018 Feb 17;18(1):194. doi: 10.1186/s12885-018-4059-5.

20.

LINE-1 as a therapeutic target for castration-resistant prostate cancer.

Houede N, Piazza PV, Pourquier P.

Front Biosci (Landmark Ed). 2018 Jan 1;23:1292-1309. Review.

PMID:
28930600
21.

Radium 223 dichloride for prostate cancer treatment.

Deshayes E, Roumiguie M, Thibault C, Beuzeboc P, Cachin F, Hennequin C, Huglo D, Rozet F, Kassab-Chahmi D, Rebillard X, Houédé N.

Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. doi: 10.2147/DDDT.S122417. eCollection 2017. Review.

22.

Prospective Evaluation of the Impact of Antiangiogenic Treatment on Cognitive Functions in Metastatic Renal Cancer.

Joly F, Heutte N, Duclos B, Noal S, Léger-Hardy I, Dauchy S, Longato N, Desrues L, Houede N, Lange M, Sevin E, Rieux C, Clarisse B, Castel H, Escudier B.

Eur Urol Focus. 2016 Dec 15;2(6):642-649. doi: 10.1016/j.euf.2016.04.009. Epub 2016 May 17.

PMID:
28723499
23.

Ductal adenocarcinoma of the prostate: Clinical and biological profiles.

Vinceneux A, Bruyère F, Haillot O, Charles T, de la Taille A, Salomon L, Allory Y, Ouzaid I, Choudat L, Rouprêt M, Comperat E, Houede N, Beauval JB, Vourc'h P, Fromont G.

Prostate. 2017 Sep;77(12):1242-1250. doi: 10.1002/pros.23383. Epub 2017 Jul 12.

PMID:
28699202
24.

Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer.

Mbatchi LC, Gassiot M, Pourquier P, Goberna A, Mahammedi H, Mourey L, Joly F, Lumbroso S, Evrard A, Houede N.

Cancer Chemother Pharmacol. 2017 Sep;80(3):653-659. doi: 10.1007/s00280-017-3379-5. Epub 2017 Jul 4.

PMID:
28676933
25.

[CCAFU french national guidelines 2016-2018 on bladder cancer].

Rouprêt M, Neuzillet Y, Masson-Lecomte A, Colin P, Compérat E, Dubosq F, Houédé N, Larré S, Pignot G, Puech P, Roumiguié M, Xylinas E, Méjean A.

Prog Urol. 2016 Nov;27 Suppl 1:S67-S91. doi: 10.1016/S1166-7087(16)30704-7. Review. French.

PMID:
27846935
26.

[CCAFU french national guidelines 2016-2018 on upper tract tumors].

Rouprêt M, Colin P, Xylinas E, Compérat E, Dubosq F, Houédé N, Larré S, Masson-Lecomte A, Neuzillet Y, Pignot G, Puech P, Roumiguié M, Méjean A.

Prog Urol. 2016 Nov;27 Suppl 1:S55-S66. doi: 10.1016/S1166-7087(16)30703-5. Review. French.

PMID:
27846934
27.

Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy.

Houédé N, Locker G, Lucas C, Parra HS, Basso U, Spaeth D, Tambaro R, Basterretxea L, Morelli F, Theodore C, Lusuardi L, Lainez N, Guillot A, Tonini G, Bielle J, Del Muro XG.

BMC Cancer. 2016 Sep 23;16(1):752.

28.

Statistical controversies in clinical research: should schedules of tumor size assessments be changed?

Filleron T, Kouokam W, Gilhodes J, Duhamel A, Penel N, Joly F, Tresch-Bruneel E, Kramar A, Houédé N.

Ann Oncol. 2016 Nov;27(11):1981-1987. Epub 2016 Aug 8. Review.

29.

Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.

de Morrée ES, Vogelzang NJ, Petrylak DP, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, Ochoa de Olza M, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, Li JS, de Wit R.

JAMA Oncol. 2017 Jan 1;3(1):68-75. doi: 10.1001/jamaoncol.2016.3000.

PMID:
27560549
30.

Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort.

Pouessel D, Bastuji-Garin S, Houédé N, Vordos D, Loriot Y, Chevreau C, Sevin E, Beuzeboc P, Taille A, Le Thuaut A, Allory Y, Culine S.

Clin Genitourin Cancer. 2017 Feb;15(1):e45-e52. doi: 10.1016/j.clgc.2016.07.012. Epub 2016 Jul 21.

PMID:
27554584
31.

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, Bögemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Houédé N, Hussain S, Lam E, Polikoff J, Stenzl A, Mainwaring P, Ramies D, Hessel C, Weitzman A, Fizazi K.

J Clin Oncol. 2016 Sep 1;34(25):3005-13. doi: 10.1200/JCO.2015.65.5597. Epub 2016 Jul 11.

PMID:
27400947
32.

Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers.

Lebret T, Neuzillet Y, Houede N, Rebouissou S, Bernard-Pierrot I, De Reynies A, Benhamou S, Allory Y, Radvanyi F.

Mol Cell Oncol. 2015 Jul 9;2(4):e999507. doi: 10.1080/23723556.2014.999507. eCollection 2015 Oct-Dec.

33.

Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.

Oudard S, Joly F, Geoffrois L, Laguerre B, Houede N, Barthelemy P, Gross-Goupil M, Vano Y, Lucidarme O, Bidault F, Kelkouli N, Slimane K, Escudier B.

Clin Genitourin Cancer. 2016 Dec;14(6):e595-e607. doi: 10.1016/j.clgc.2016.04.019. Epub 2016 May 2.

PMID:
27283478
34.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW.

Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18.

35.

[Observational survey of the French Urological Association Oncology Committee (CCAFU) evaluating the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment].

Neuzillet Y, Colin P, Comperat E, Dubosq F, Houede N, Larre S, Masson-Lecomte A, Pignot G, Puech P, Roumiguie M, Xylinas E, Mejean A, Roupret M.

Prog Urol. 2016 Mar;26(3):181-90. doi: 10.1016/j.purol.2015.12.002. Epub 2016 Jan 8. French.

PMID:
26777686
36.

[Molecular, preclinical, and clinical comparative data regarding different strains of bacillus Calmette-Guérin (BCG): Review by the French Urological Association Oncology Committee (CCAFU)].

Neuzillet Y, Dubosq F, Xylinas E, Colin P, Comperat E, Houede N, Larre S, Masson-Lecomte A, Pignot G, Puech P, Roumiguie M, Mejean A, Roupret M.

Prog Urol. 2016 Feb;26(2):121-8. doi: 10.1016/j.purol.2015.10.011. Epub 2015 Nov 27. Review. French.

PMID:
26638801
37.

Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.

Blanchard P, Faivre L, Lesaunier F, Salem N, Mesgouez-Nebout N, Deniau-Alexandre E, Rolland F, Ferrero JM, Houédé N, Mourey L, Théodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Davin JL, Habibian M, Culine S, Laplanche A, Fizazi K.

Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):85-92. doi: 10.1016/j.ijrobp.2015.09.020. Epub 2015 Sep 25.

PMID:
26576711
38.

Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients.

Roubaud G, Brouste V, Beuzeboc P, Fléchon A, Tosi D, Lavau-Denes S, Chevreau C, Culine S, Oudard S, Quivy A, Pourquier P, Houédé N.

J Negat Results Biomed. 2015 Nov 10;14:18. doi: 10.1186/s12952-015-0037-5.

39.

Le cancer de vessie chez le sujet jeune, une étude de population française.

Compérat E, Larré S, Neuzillet Y, Vordos D, Soulié M, Azzouzi A, Pignot G, Durand X, Quintens H, Houede N, Jeglischi S, El Bakri A, Bigot P, Lebdai S, Rouprêt M, Pfister C.

Prog Urol. 2014 Nov;24(13):846. doi: 10.1016/j.purol.2014.08.140. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461667
40.

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.

Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F, Bossi A, Bracarda S, Bukowski R, Catto J, Choueiri TK, Crabb S, Eisen T, El Demery M, Fitzpatrick J, Flamand V, Goebell PJ, Gravis G, Houédé N, Jacqmin D, Kaplan R, Malavaud B, Massard C, Melichar B, Mourey L, Nathan P, Pasquier D, Porta C, Pouessel D, Quinn D, Ravaud A, Rolland F, Schmidinger M, Tombal B, Tosi D, Vauleon E, Volpe A, Wolter P, Escudier B, Filleron T; DATECAN Renal Cancer group.

Ann Oncol. 2015 Dec;26(12):2392-8. doi: 10.1093/annonc/mdv380. Epub 2015 Sep 14. Review.

41.

[Follow-up of urothelial carcinoma: Review of the Cancer Committee of the French Association of Urology].

Colin P, Neuzillet Y, Pignot G, Rouprêt M, Comperat E, Larré S, Roy C, Quintens H, Houedé N, Soulié M, Pfister C; membres du Comité de cancérologie de l’Association française d’urologie.

Prog Urol. 2015 Sep;25(10):616-24. doi: 10.1016/j.purol.2015.05.012. Epub 2015 Jun 30. Review. French.

PMID:
26141291
42.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S.

Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28.

PMID:
26028518
43.

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.

Houédé N, Beuzeboc P, Gourgou S, Tosi D, Moise L, Gravis G, Delva R, Fléchon A, Latorzeff I, Ferrero JM, Oudard S, Tartas S, Laguerre B, Topart D, Roubaud G, Agherbi H, Rebillard X, Azria D.

BMC Cancer. 2015 Apr 4;15:222. doi: 10.1186/s12885-015-1257-2.

44.

Formal consensus method to evaluate the conformity of prescription of a recently approved chemotherapy treatment in an observatory study.

Houédé N, Leutenegger E, Lomma M, Bellera C.

PLoS One. 2015 Apr 2;10(4):e0123035. doi: 10.1371/journal.pone.0123035. eCollection 2015.

45.

Dynamic contrast enhanced MRI-derived parameters are potential biomarkers of therapeutic response in bladder carcinoma.

Chakiba C, Cornelis F, Descat E, Gross-Goupil M, Sargos P, Roubaud G, Houédé N.

Eur J Radiol. 2015 Jun;84(6):1023-8. doi: 10.1016/j.ejrad.2015.02.026. Epub 2015 Mar 6.

PMID:
25796426
46.

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K.

Lancet Oncol. 2015 Apr;16(4):417-25. doi: 10.1016/S1470-2045(15)70025-2. Epub 2015 Mar 3.

PMID:
25743937
47.

Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old.

Compérat E, Larré S, Roupret M, Neuzillet Y, Pignot G, Quintens H, Houéde N, Roy C, Durand X, Varinot J, Vordos D, Rouanne M, Bakhri MA, Bertrand P, Jeglinschi SC, Cussenot O, Soulié M, Pfister C.

Virchows Arch. 2015 May;466(5):589-94. doi: 10.1007/s00428-015-1739-2. Epub 2015 Feb 20.

PMID:
25697540
48.

[Tasquinimod: How to act on microenvironment in metastatic prostate cancer].

Houédé N, Irani J.

Prog Urol. 2015 May;25(6):298-305. doi: 10.1016/j.purol.2015.01.008. Epub 2015 Feb 13. Review. French.

PMID:
25684391
49.

[Professional's expectations to improve quality of care and social services utilization in geriatric oncology].

Antoine V, de Wazières B, Houédé N.

Bull Cancer. 2015 Feb;102(2):150-61. doi: 10.1016/j.bulcan.2014.12.011. Epub 2015 Jan 30. French.

PMID:
25649352
50.

Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma.

Houédé N, Dupuy L, Fléchon A, Beuzeboc P, Gravis G, Laguerre B, Théodore C, Culine S, Filleron T, Chevreau C.

BJU Int. 2016 Mar;117(3):444-9. doi: 10.1111/bju.13054. Epub 2015 Apr 27.

Supplemental Content

Loading ...
Support Center